Shanghai Fosun Pharmaceutical falls as Alzheimer drug hits a snag

By Reuters News

** Hong Kong shares of Shanghai Fosun Pharmaceutical drop 10.9% to HK$14.42, their lowest level since May 2025

** Shanghai-listed stock 600196.SS fall 8.6% to 20.4 yuan, the lowest point since February 2024

** Company says its unit plans to license an Alzheimer's disease drug from South Korean pharmaceutical firm AriBio Co Ltd this year and will decide whether to exercise an option to formally license the drug once the results of the Phase III clinical trials are available

** Data from Phase III clinical trial of oral drug AR1001 showed that primary endpoint achieved statistical significance in monotherapy group, meeting the primary efficacy objective, but the difference between the treatment group and the placebo group did not reach statistical significance in overall polulation - co

** Company said it will further analyze and evaluate the research data related to AR1001 to determine whether to exercise the option

** YTD, Hong Kong stock down 23.9%, Shanghai-listed shares down 21.3%

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.